Close Menu

NEW YORK – ProciseDx said Friday that it has received the CE mark for its Procise CRP (C-reactive protein) assay.

The company said it is completing its first clinical trials in the US and plans to apply for marketing clearance to the US Food and Drug Administration for its instrument and Procise CRP assay in the first quarter of this year. 

In September last year, the firm had announced it received the CE mark for its point-of-care immunoassay instrument.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.